Relationships between monocyte count to high-density lipoprotein cholesterol ratio and cardiovascular outcomes in

Dongryul Kim1, Da Won Kim1, Yeon Hee Lee1

  • 1Division of Nephrology, Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea.

Insights

The monocyte to HDL cholesterol ratio (MHR) may predict cardiovascular events in dialysis patients. A high MHR indicates a higher risk of cardiovascular complications, even if overall mortality is similar.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomarkers

Background:

  • High monocyte to HDL cholesterol ratio (MHR) is a known cardiovascular risk factor.
  • Patients commencing dialysis are at increased risk for cardiovascular complications.

Purpose of the Study:

  • To investigate the association between MHR and cardiovascular outcomes in patients starting dialysis.
  • To determine if MHR predicts cardiovascular events in this high-risk population.

Main Methods:

  • Retrospective review of medical records for 597 patients initiating maintenance dialysis (2006-2017).
  • Patients were categorized into low-MHR and high-MHR groups.
  • Primary outcomes: all-cause mortality, CV mortality. Secondary outcomes: CV event-free survival, CV complication incidence.

Main Results:

  • No significant difference in all-cause or CV mortality between low- and high-MHR groups.
  • Significantly lower CV event-free survival in the high-MHR group (47.5% vs. 59.0%).
  • High MHR independently predicted cardiovascular events (HR 1.886, 95% CI 1.015-3.505).

Conclusions:

  • High MHR at dialysis initiation is associated with poorer cardiovascular event-free survival.
  • MHR may serve as a valuable predictor of cardiovascular complications in dialysis patients.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
390
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
146
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
335
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
106
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
192